Lucintel Newsletter

Business News by Lucintel

Bookmark and Share

Sunday, March 22, 2026

Lucintel Forecasts the Global Scopolamine Hydrobromide Market to Grow with a CAGR of 4.1% from 2025 to 2031

According to a market report by Lucintel, the future of the global scopolamine hydrobromide market looks promising with opportunities in the hospital and clinic markets. The global scopolamine hydrobromide market is expected to grow with a CAGR of 4.1% from 2025 to 2031. The major drivers for this market are the increasing prevalence of motion sickness disorders, the rising demand for postoperative nausea treatments, and the growing use in pharmaceutical injectable formulations.

A more than 150-page report to understand trends, opportunity and forecast in global scopolamine hydrobromide market to 2031 by type (injections, oral, and topical), application (hospital and clinic), and region (North America, Europe, Asia Pacific, and the Rest of the World).

Lucintel forecasts that, within the type category, injection is expected to witness the highest growth over the forecast period.

Within the application category, hospital is expected to witness higher growth.

Download sample by clicking on scopolamine hydrobromide market.

In terms of region, APAC is expected to witness the highest growth over the forecast period.

Novartis, Mylan, Teva Pharmaceuticals, Baxter International, Sandoz, Amgen, Accord Healthcare, Manus Aktteva Biopharma, ALKALOIDS CORPORATION, Sigma-Aldrich  are the major suppliers in the scopolamine hydrobromide market.

This unique research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or write us at helpdesk@lucintel.com. To get access of more than 1000 reports at fraction of cost visit Lucintel's Analytics Dashboard.

About Lucintel

At Lucintel, we offer solutions for you growth through game changer ideas and robust market & unmet needs analysis. We are based in Dallas, TX and have been a trusted advisor for 1,000+ clients for over 20 years. We are quoted in several publications like the Wall Street Journal, ZACKS, and the Financial Times.

Contact:
Roy Almaguer
Lucintel
Dallas, Texas, USA
Email:
roy.almaguer@lucintel.com
Tel. +1-972-636-5056

Explore Our Latest Publications

Hidradenitis Suppurativa Treatment Market

Hospital Commode Market

Hydromassage Table Market

IVUS-OCT Market

LiDAR Perimeter Detection Market

 

No comments:

Post a Comment